Characteristics and Management of Uncontrolled Gout Prior to Pegloticase Therapy: A 2-year Claims Analysis
Abstract Objective Gout is a progressive form of arthritis that causes significant pain and disability. Patients with treatment-refractory (or uncontrolled) gout experience a higher prevalence and severity of comorbidities than those whose gout is controlled. Pegloticase is a recombinant PEGylated u...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-11-01
|
| Series: | Rheumatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40744-024-00723-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585340602286080 |
|---|---|
| author | Robert J. Morlock Deepan Dalal Victoria Divino Mitchell DeKoven Stephanie D. Taylor Atsuko Powers Naina Barretto Robert J. Holt Brian LaMoreaux |
| author_facet | Robert J. Morlock Deepan Dalal Victoria Divino Mitchell DeKoven Stephanie D. Taylor Atsuko Powers Naina Barretto Robert J. Holt Brian LaMoreaux |
| author_sort | Robert J. Morlock |
| collection | DOAJ |
| description | Abstract Objective Gout is a progressive form of arthritis that causes significant pain and disability. Patients with treatment-refractory (or uncontrolled) gout experience a higher prevalence and severity of comorbidities than those whose gout is controlled. Pegloticase is a recombinant PEGylated uricase indicated for the treatment of gout in patients refractory to conventional therapy. We evaluated the treatment journey of patients with chronic uncontrolled gout before initiation of pegloticase therapy. Methods Using IQVIA’s PharMetrics® Plus database, we conducted a retrospective observational analysis of adults with ≥ 1 pegloticase claim between April 1, 2011, and August 31, 2020. Demographics were assessed at baseline. Clinical outcomes, health care resource utilization (HCRU), and associated costs were compared over two 12-month periods (months 13–24 and 1–12) prior to the first pegloticase claim (index date). Results The study included 408 patients. Prevalence of all gout-associated conditions increased between months 1–12 and 13–24 (P < 0.05 for all). The percentage of patients with tophi increased from 15.4% to 61.5%, the percentage with ≥ 1 flare increased from 49% to 84%, and mean number of flares per patient increased from 1.0 to 2.1 (P < 0.0001 for all). The frequency of all categories of HCRU except emergency department visits also increased (P < 0.0001 for all), as did gout-related healthcare utilization (P£0.005). Conclusions Patients with uncontrolled gout experienced an increase in the clinical burden of disease and HCRU in the 2 years before the initiation of pegloticase. Earlier patient identification and initiation of potentially effective therapy may help alleviate these burdens. |
| format | Article |
| id | doaj-art-25a69d0713de4308b4517109ff9f3b8c |
| institution | Kabale University |
| issn | 2198-6576 2198-6584 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Rheumatology and Therapy |
| spelling | doaj-art-25a69d0713de4308b4517109ff9f3b8c2025-01-26T12:52:10ZengAdis, Springer HealthcareRheumatology and Therapy2198-65762198-65842024-11-01121375110.1007/s40744-024-00723-9Characteristics and Management of Uncontrolled Gout Prior to Pegloticase Therapy: A 2-year Claims AnalysisRobert J. Morlock0Deepan Dalal1Victoria Divino2Mitchell DeKoven3Stephanie D. Taylor4Atsuko Powers5Naina Barretto6Robert J. Holt7Brian LaMoreaux8YourCareChoiceDivision of Rheumatology, Brown University Warren Alpert Medical SchoolHealth Economics/Outcomes Research and Real-World Insights, IQVIAHealth Economics/Outcomes Research and Real-World Insights, IQVIAHorizon Therapeutics (Now Amgen Inc.)Horizon Therapeutics (Now Amgen Inc.)Horizon Therapeutics (Now Amgen Inc.)Horizon Therapeutics (Now Amgen Inc.)Horizon Therapeutics (Now Amgen Inc.)Abstract Objective Gout is a progressive form of arthritis that causes significant pain and disability. Patients with treatment-refractory (or uncontrolled) gout experience a higher prevalence and severity of comorbidities than those whose gout is controlled. Pegloticase is a recombinant PEGylated uricase indicated for the treatment of gout in patients refractory to conventional therapy. We evaluated the treatment journey of patients with chronic uncontrolled gout before initiation of pegloticase therapy. Methods Using IQVIA’s PharMetrics® Plus database, we conducted a retrospective observational analysis of adults with ≥ 1 pegloticase claim between April 1, 2011, and August 31, 2020. Demographics were assessed at baseline. Clinical outcomes, health care resource utilization (HCRU), and associated costs were compared over two 12-month periods (months 13–24 and 1–12) prior to the first pegloticase claim (index date). Results The study included 408 patients. Prevalence of all gout-associated conditions increased between months 1–12 and 13–24 (P < 0.05 for all). The percentage of patients with tophi increased from 15.4% to 61.5%, the percentage with ≥ 1 flare increased from 49% to 84%, and mean number of flares per patient increased from 1.0 to 2.1 (P < 0.0001 for all). The frequency of all categories of HCRU except emergency department visits also increased (P < 0.0001 for all), as did gout-related healthcare utilization (P£0.005). Conclusions Patients with uncontrolled gout experienced an increase in the clinical burden of disease and HCRU in the 2 years before the initiation of pegloticase. Earlier patient identification and initiation of potentially effective therapy may help alleviate these burdens.https://doi.org/10.1007/s40744-024-00723-9GoutHealth services researchRegistryUric acidFlarePegloticase |
| spellingShingle | Robert J. Morlock Deepan Dalal Victoria Divino Mitchell DeKoven Stephanie D. Taylor Atsuko Powers Naina Barretto Robert J. Holt Brian LaMoreaux Characteristics and Management of Uncontrolled Gout Prior to Pegloticase Therapy: A 2-year Claims Analysis Rheumatology and Therapy Gout Health services research Registry Uric acid Flare Pegloticase |
| title | Characteristics and Management of Uncontrolled Gout Prior to Pegloticase Therapy: A 2-year Claims Analysis |
| title_full | Characteristics and Management of Uncontrolled Gout Prior to Pegloticase Therapy: A 2-year Claims Analysis |
| title_fullStr | Characteristics and Management of Uncontrolled Gout Prior to Pegloticase Therapy: A 2-year Claims Analysis |
| title_full_unstemmed | Characteristics and Management of Uncontrolled Gout Prior to Pegloticase Therapy: A 2-year Claims Analysis |
| title_short | Characteristics and Management of Uncontrolled Gout Prior to Pegloticase Therapy: A 2-year Claims Analysis |
| title_sort | characteristics and management of uncontrolled gout prior to pegloticase therapy a 2 year claims analysis |
| topic | Gout Health services research Registry Uric acid Flare Pegloticase |
| url | https://doi.org/10.1007/s40744-024-00723-9 |
| work_keys_str_mv | AT robertjmorlock characteristicsandmanagementofuncontrolledgoutpriortopegloticasetherapya2yearclaimsanalysis AT deepandalal characteristicsandmanagementofuncontrolledgoutpriortopegloticasetherapya2yearclaimsanalysis AT victoriadivino characteristicsandmanagementofuncontrolledgoutpriortopegloticasetherapya2yearclaimsanalysis AT mitchelldekoven characteristicsandmanagementofuncontrolledgoutpriortopegloticasetherapya2yearclaimsanalysis AT stephaniedtaylor characteristicsandmanagementofuncontrolledgoutpriortopegloticasetherapya2yearclaimsanalysis AT atsukopowers characteristicsandmanagementofuncontrolledgoutpriortopegloticasetherapya2yearclaimsanalysis AT nainabarretto characteristicsandmanagementofuncontrolledgoutpriortopegloticasetherapya2yearclaimsanalysis AT robertjholt characteristicsandmanagementofuncontrolledgoutpriortopegloticasetherapya2yearclaimsanalysis AT brianlamoreaux characteristicsandmanagementofuncontrolledgoutpriortopegloticasetherapya2yearclaimsanalysis |